Joshua Foukas Sells 4,461 Shares of USANA Health Sciences (NYSE:USNA) Stock

USANA Health Sciences, Inc. (NYSE:USNAGet Free Report) insider Joshua Foukas sold 4,461 shares of the business’s stock in a transaction that occurred on Friday, February 20th. The shares were sold at an average price of $21.34, for a total transaction of $95,197.74. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

USANA Health Sciences Price Performance

NYSE USNA opened at $21.63 on Wednesday. The company’s 50 day simple moving average is $20.76 and its two-hundred day simple moving average is $23.35. USANA Health Sciences, Inc. has a 1 year low of $18.48 and a 1 year high of $38.32. The stock has a market capitalization of $395.31 million, a PE ratio of 39.32, a P/E/G ratio of 0.91 and a beta of 0.67.

USANA Health Sciences (NYSE:USNAGet Free Report) last released its quarterly earnings results on Tuesday, February 17th. The company reported $0.60 earnings per share for the quarter, beating the consensus estimate of $0.41 by $0.19. USANA Health Sciences had a return on equity of 6.75% and a net margin of 1.16%.The firm had revenue of $226.20 million for the quarter, compared to analysts’ expectations of $225.96 million. On average, research analysts anticipate that USANA Health Sciences, Inc. will post 2.45 EPS for the current year.

Wall Street Analyst Weigh In

USNA has been the subject of several research analyst reports. Weiss Ratings restated a “sell (d)” rating on shares of USANA Health Sciences in a report on Monday, December 29th. Zacks Research raised shares of USANA Health Sciences from a “strong sell” rating to a “hold” rating in a report on Monday, February 16th. Finally, Wall Street Zen raised USANA Health Sciences from a “hold” rating to a “buy” rating in a report on Saturday. Two investment analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Reduce” and a consensus price target of $36.00.

Check Out Our Latest Report on USANA Health Sciences

Institutional Trading of USANA Health Sciences

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. State of Tennessee Department of Treasury lifted its position in shares of USANA Health Sciences by 307.8% during the 4th quarter. State of Tennessee Department of Treasury now owns 29,290 shares of the company’s stock valued at $636,000 after buying an additional 22,108 shares in the last quarter. Empowered Funds LLC raised its stake in USANA Health Sciences by 10.6% during the 4th quarter. Empowered Funds LLC now owns 60,437 shares of the company’s stock worth $1,186,000 after acquiring an additional 5,782 shares during the period. Tudor Investment Corp ET AL raised its stake in USANA Health Sciences by 354.8% during the 4th quarter. Tudor Investment Corp ET AL now owns 109,686 shares of the company’s stock worth $2,153,000 after acquiring an additional 85,570 shares during the period. Numerai GP LLC purchased a new position in USANA Health Sciences during the fourth quarter valued at approximately $1,027,000. Finally, Millennium Management LLC boosted its position in shares of USANA Health Sciences by 715.7% in the fourth quarter. Millennium Management LLC now owns 285,416 shares of the company’s stock worth $5,603,000 after purchasing an additional 250,424 shares during the period. Hedge funds and other institutional investors own 54.25% of the company’s stock.

USANA Health Sciences Company Profile

(Get Free Report)

USANA Health Sciences, Inc is a Utah‐based company that develops, manufactures and distributes nutritional supplements and personal care products through a network of independent distributors. Founded in 1992 by Dr. Myron Wentz, the company’s portfolio includes vitamins, minerals, dietary supplements, weight‐management products and skin‐care formulations. USANA’s products are formulated in its own laboratories to meet pharmaceutical‐grade standards, and the company has invested heavily in research and development and quality control to support its offerings.

Operating primarily through a direct selling model, USANA serves markets in North America, Asia Pacific, Europe and Latin America.

Featured Articles

Insider Buying and Selling by Quarter for USANA Health Sciences (NYSE:USNA)

Receive News & Ratings for USANA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.